| review article | Q7318358 |
| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017730776 |
| P356 | DOI | 10.1007/S00592-014-0698-4 |
| P932 | PMC publication ID | 4506471 |
| P698 | PubMed publication ID | 25585592 |
| P5875 | ResearchGate publication ID | 270909691 |
| P50 | author | Maciej T. Małecki | Q89424369 |
| Piotr Wojciechowski | Q60312713 | ||
| P2093 | author name string | Przemyslaw Rys | |
| Joanna Lis | |||
| Agnieszka Rogoz-Sitek | |||
| Albert Syta | |||
| Grzegorz Niesyczyński | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
| Insulin detemir versus insulin glargine for type 2 diabetes mellitus | Q24235596 | ||
| Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus | Q24245192 | ||
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies | Q26823071 | ||
| Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies | Q27025720 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Standards of medical care in diabetes--2014 | Q28304435 | ||
| Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes | Q33853992 | ||
| Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs | Q33984638 | ||
| ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab | Q34368081 | ||
| Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes | Q34381425 | ||
| Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. | Q34449820 | ||
| Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes | Q34594675 | ||
| Insulin glargine: a new basal insulin | Q34648626 | ||
| Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients | Q34663438 | ||
| Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures | Q34982117 | ||
| American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan | Q83808238 | ||
| Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine | Q83874724 | ||
| Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial | Q84701617 | ||
| Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial | Q85154736 | ||
| Diabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan | Q86424484 | ||
| Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes | Q47222394 | ||
| A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. | Q48432586 | ||
| Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes. | Q51534382 | ||
| Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. | Q51941134 | ||
| A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes | Q53862758 | ||
| Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. | Q55034466 | ||
| U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group | Q56914456 | ||
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 | ||
| Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride | Q79370979 | ||
| Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis | Q81317578 | ||
| Intensive glucose control and macrovascular outcomes in type 2 diabetes. | Q34995674 | ||
| Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. | Q35038355 | ||
| Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues | Q36274535 | ||
| Efficacy of biphasic insulin aspart in patients with type 2 diabetes | Q36414686 | ||
| Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials | Q36426817 | ||
| A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes | Q36449523 | ||
| Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes | Q36602652 | ||
| A review of human and analogue insulin trials | Q36656636 | ||
| Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study | Q36720223 | ||
| Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison | Q37013205 | ||
| DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes | Q37189266 | ||
| Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study | Q37296843 | ||
| Epidemiological aspects of neoplasms in diabetes | Q37727058 | ||
| Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir | Q37815511 | ||
| Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes | Q37818351 | ||
| Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis | Q37964744 | ||
| Systematic review and meta-analysis of insulin therapy and risk of cancer. | Q38005000 | ||
| Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemi | Q38371451 | ||
| Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials | Q38898058 | ||
| A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. | Q40717578 | ||
| Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 | ||
| Effect of normalization of fasting glucose by intensified insulin therapy and influence of eNOS polymorphisms on the incidence of restenosis after peripheral angioplasty in patients with type 2 diabetes: a randomized, open-label clinical trial. | Q42511510 | ||
| A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes | Q42607495 | ||
| Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile | Q42790410 | ||
| Severe hypoglycemia and risks of vascular events and death | Q42868535 | ||
| Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus | Q43075550 | ||
| Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials | Q43080195 | ||
| Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study | Q43187037 | ||
| Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. | Q43263307 | ||
| Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin | Q43584177 | ||
| Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial | Q44479625 | ||
| The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients | Q44631767 | ||
| Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes | Q45242316 | ||
| Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. | Q45946807 | ||
| Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry | Q46220548 | ||
| Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial | Q46308233 | ||
| Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes | Q46406475 | ||
| Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week | Q46834143 | ||
| Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pi | Q46866724 | ||
| Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study | Q46926372 | ||
| Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy | Q46953005 | ||
| Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit | Q46963862 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | hormone | Q11364 |
| preproinsulin | Q7240673 | ||
| insulin detemir | Q410965 | ||
| insulin glargine | Q417317 | ||
| meta-analysis | Q815382 | ||
| peptide | Q172847 | ||
| systematic review | Q1504425 | ||
| NPH insulin | Q1929845 | ||
| type 2 diabetes | Q3025883 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 649-662 | |
| P577 | publication date | 2015-01-14 | |
| 2015-08-01 | |||
| P1433 | published in | Acta Diabetologica | Q15749690 |
| P1476 | title | Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus | |
| P478 | volume | 52 |
| Q64928655 | Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. |
| Q98288263 | Basal Insulin Dose Titration for Glycemic Control in Patients With Type 2 Diabetes Mellitus in Thailand: Results of the REWARDS Real-World Study |
| Q64239470 | Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment |
| Q64908000 | Body Weight Considerations in the Management of Type 2 Diabetes. |
| Q49823996 | Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study. |
| Q53484316 | Comparative effectiveness and safety of different basal insulins in a real-world setting. |
| Q47097108 | Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline |
| Q36928047 | Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus |
| Q47132365 | Déprescription des antihyperglycémiants chez les personnes âgées: Guide de pratique clinique fondé sur les données probantes |
| Q52605864 | Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. |
| Q51284596 | Enhanced external counterpulsation (EECP) improves biomarkers of glycemic control in patients with non-insulin-dependent type II diabetes mellitus for up to 3 months following treatment. |
| Q40963671 | Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs |
| Q92684714 | HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs |
| Q92423884 | Human Insulin Versus Insulin Analogues: A True Companion Forgotten |
| Q91787174 | Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting |
| Q38639583 | Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization |
| Q39294616 | Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization |
| Q53598738 | Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults. |
| Q52591845 | Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. |
| Q47770450 | Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin |
| Q28078467 | Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis |
| Q48088343 | Switching basal insulins in type 2 diabetes: practical recommendations for health care providers |
| Q38983622 | Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. |
| Q64893414 | Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia. |
| Q52836101 | [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE]. |
Search more.